Biodexa Pharmaceuticals (STU:5MP2) Tariff Resilience Score: 5/10 (As of Jun. 25, 2026)


STU:5MP2 Biodexa Pharmaceuticals PLC STU:5MP2
10 GF Score
Price €110,400.00
GF Value €95,593.41
View Full Analysis

What is Biodexa Pharmaceuticals Tariff Resilience Score?

Biodexa Pharmaceuticals STU:5MP2 10 Tariff Resilience Score is 5 as of Jun. 25, 2026. GuruFocus rates STU:5MP2 with a GF Score™ of 10/100 and a GF Value™ of €95,593.41. Among 1,379 Biotechnology companies, Biodexa Pharmaceuticals ranks better than 62.22% on this metric.

Biodexa Pharmaceuticals has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Biodexa Pharmaceuticals has Moderate exposure due to reliance on international supply chains for raw materials. However, its focus on niche pharmaceutical products may offer some pricing flexibility.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Biodexa Pharmaceuticals might have Average Resilient.

Biodexa Pharmaceuticals  (STU:5MP2) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Biodexa Pharmaceuticals Tariff Resilience Score Related Terms

STU:5MP2 vs CASIF, OGEN, ELOX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Biodexa Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biodexa Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biodexa Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Biodexa Pharmaceuticals's Tariff Resilience Score falls into.


STU:5MP2
10GF Score
Biodexa Pharmaceuticals PLC STU:5MP2
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Biodexa Pharmaceuticals (STU:5MP2) has a Tariff Resilience Score of 5 as of Jun. 25, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Biodexa Pharmaceuticals ranks #521 out of 1379 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Biodexa Pharmaceuticals' Tariff Resilience Score too high?
Biodexa Pharmaceuticals' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Biodexa Pharmaceuticals' value of 5 is 25% above this industry median. Based on the distribution chart, Biodexa Pharmaceuticals ranks #521 out of 1379 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biodexa Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Tariff Resilience Score compare to CASIF and OGEN?
According to the Biotechnology industry distribution chart, Biodexa Pharmaceuticals ranks #521 out of 1379 companies for Tariff Resilience Score. This puts Biodexa Pharmaceuticals in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Biodexa Pharmaceuticals' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biodexa Pharmaceuticals's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biodexa Pharmaceuticals's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (STU:5MP2) has a current Tariff Resilience Score of 5. The stock's GF Value™ is €95,593.41, compared to a current price of €110,400.00 — trading 15.5% above its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Biodexa Pharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Biodexa Pharmaceuticals (STU:5MP2), the current Tariff Resilience Score is 5 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.

Key valuation signals for STU:5MP2:

  • Tariff Resilience Score: 5
  • GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
  • GF Score™: 10/100
  • Industry Position: 25% above the Biotechnology median (#521 of 1379)

No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Other Exchanges BDRX:USA
Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
10GF Score

Get the complete analysis for STU:5MP2

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€110,400.00
Price
€95,593.41
GF Value